Back to Search Start Over

Protein structural insights into a rare PCSK9 gain-of-function variant (R496W) causing familial hypercholesterolemia in a Saudi family: whole exome sequencing and computational analysis.

Authors :
Shaik NA
Al-Shehri N
Athar M
Awan A
Khalili M
Al Mahadi HB
Hejazy G
Saadah OI
Al-Harthi SE
Elango R
Banaganapalli B
Alefishat E
Awan Z
Source :
Frontiers in physiology [Front Physiol] 2023 Jul 04; Vol. 14, pp. 1204018. Date of Electronic Publication: 2023 Jul 04 (Print Publication: 2023).
Publication Year :
2023

Abstract

Familial hypercholesterolemia (FH) is a globally underdiagnosed genetic condition associated with premature cardiovascular death. The genetic etiology data on Arab FH patients is scarce. Therefore, this study aimed to identify the genetic basis of FH in a Saudi family using whole exome sequencing (WES) and multidimensional bioinformatic analysis. Our WES findings revealed a rare heterozygous gain-of-function variant (R496W) in the exon 9 of the PCSK9 gene as a causal factor for FH in this family. This variant was absent in healthy relatives of the proband and 200 healthy normolipidemic controls from Saudi Arabia. Furthermore, this variant has not been previously reported in various regional and global population genomic variant databases. Interestingly, this variant is classified as "likely pathogenic" (PP5) based on the variant interpretation guidelines of the American College of Medical Genetics (ACMG). Computational functional characterization suggested that this variant could destabilize the native PCSK9 protein and alter its secondary and tertiary structural features. In addition, this variant was predicted to negatively influence its ligand-binding ability with LDLR and Alirocumab antibody molecules. This rare PCSK9 (R496W) variant is likely to expand our understanding of the genetic basis of FH in Saudi Arabia. This study also provides computational structural insights into the genotype-protein phenotype relationship of PCSK9 pathogenic variants and contributes to the development of personalized medicine for FH patients in the future.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Shaik, Al-Shehri, Athar, Awan, Khalili, Al Mahadi, Hejazy, Saadah, Al-Harthi, Elango, Banaganapalli, Alefishat and Awan.)

Details

Language :
English
ISSN :
1664-042X
Volume :
14
Database :
MEDLINE
Journal :
Frontiers in physiology
Publication Type :
Academic Journal
Accession number :
37469559
Full Text :
https://doi.org/10.3389/fphys.2023.1204018